Alex Goldberg

NASDAQ Gainers Watch List: Celgene Corporation (NASDAQ:CELG) and YY Inc. (NASDAQ:YY) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/09/2014 -- Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Celgene Corporation (NASDAQ:CELG) and YY Inc. (NASDAQ:YY).

Celgene Corporation (NASDAQ:CELG) a company that discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe closed up in its previous session (+1.73%) on 2,656,990 shares traded after ABRAXANE Plus gemcitabine Received European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer. Celgene Corporation (NASDAQ:CELG) is currently up (+86.47%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about Celgene Corporation (NASDAQ:CELG)

YY Inc. (NASDAQ:YY) a company that through its subsidiaries, operates an online social platform in the Peoples Republic of China closed up in its previous session (+1.93%) on 2,463,578 shares traded. YY Inc. (NASDAQ:YY) is currently up (+393.87%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List.

Click Here to find out what other Investors are saying about YY Inc. (NASDAQ:YY)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com